Participated · Equity · Jun 2026

Seat Unique operates a premium ticketing and hospitality platform that markets original ticketing inventory and provides hospitality and travel packages for rights-holders, venues, artists, sports teams and fans. The company has expanded via acquisitions including P1 Travel and Circuit Hospitality to broaden its capabilities and relationships, notably with venues such as Wembley Stadium, Manchester's Co-op Live and the 16 racecourses run by Arena Racing. Circuit Hospitality strengthened its foothold in Premier League football through agreements with Arsenal and Everton, and Seat Unique has been involved in high-profile events such as former US President Barack Obama's speaking tour. The business is run by co-founder Robin Sherry and chaired by Richard Flint. Seat Unique said it is on course to record £175m in sales this year and aims to double that over the next three years. It is pursuing further acquisitions and international expansion as part of a strategy to scale toward an ambition of a £500m-plus business valuation.

Participated · Series C · Jun 2026

Oxford Quantum Circuits, founded as a spinout from Oxford University in 2017 and based in Reading, develops superconducting quantum computing hardware and supporting software. The company deploys its machines in data centres and offers access to customers and researchers as a cloud service. OQC targets business and government customers, citing demand from financial services, defence and security companies for secure quantum technology. It positions itself to move from long-term promise toward near-term commercial delivery and plans to scale internationally and advance its technology roadmap. The company recently strengthened its financial position by raising a £260 million Series C to accelerate commercialization and market expansion. No revenue or user metrics were disclosed in the provided article.

Participated · Series A · May 2026

PlayerData began with a lower-cost GPS wearable aimed at expanding access to performance tracking and has expanded into a broader data-capture ecosystem combining wearables, GPS-embedded balls, and AI-paired video. The company plans a full commercial launch this summer for a GPS-based soccer ball developed with Puma and Mitre and is testing connected balls from Nike. A portable 8K, 190-degree camera that syncs with player and ball sensors and uses AI to automate video clipping is slated to follow. PlayerData’s wearable is in use across US Soccer, several MLS clubs, and multiple MLB teams (including the Red Sox, Rays, and Astros), and officials will wear the device at every FIFA men’s World Cup match this summer; the company holds Preferred Provider status through FIFA’s Quality Programme. The business recently raised $12M in a Series A to scale products and expand the team, has grown headcount ~40% over 18 months, and moved its U.S. headquarters to Boston.

Participated · Series B · May 2026

Brami began in 2016 as a maker of cured lupini bean snacks and introduced its protein pasta line in 2021. Its core product is a durum wheat semolina pasta fortified with milled lupini beans, a legume Brami sources from cooperatives across Europe. The company emphasizes simple ingredients and claims high protein and fiber density from the lupini inclusion, positioning the pasta as comparable in taste and texture to premium boxed pastas. Brami has rapidly expanded retail distribution—now more than 4,000 doors including upcoming national placement at Walmart, Kroger, Whole Foods, Target and Costco—and has plans for exclusive shapes and new SKUs. Management reports the brand is the fastest-growing pasta brand in the U.S., expects roughly 400% year-over-year growth by the end of 2026, and is profitable. Brami has also executed branded marketing partnerships, including one with the New York Yankees for the 2026 season.

Led · Series A · Jul 2025

Sava Technologies builds a proprietary multi-molecule biosensor powering a pain-free wearable that delivers real-time molecular insights to a smartphone. The device has demonstrated accurate glucose readings for up to 10 days in early clinical data from a 50-patient study (first 25 participants). Sava aims to address key CGM barriers—pain, cost and accessibility—and to expand beyond glucose to multi-analyte sensing for preventative and personalised healthcare. The company plans a pivotal study next year and is working toward regulatory approval and commercialisation while scaling automated manufacturing to meet launch volumes. Founded in 2019 and based in London, Sava is also pursuing interest from athletes and health-conscious consumers as it targets the global wearables market. Sava is a London, UK-based consumer and medical device company developing a wearable biosensor platform that can detect molecules just under the skin. Its novel microsensor technology monitors biomarkers in real time, starting with glucose. The company recently gained MHRA approval to proceed with clinical trials in patients with diabetes. An upcoming clinical study is scheduled to start with investigators from the Universities of Oxford and Cambridge. Sava plans to use the $8M Seed to expand its team, design its product line with manufacturing capability, and demonstrate the platform’s clinical performance. The company was founded by Renato Circi and Rafael Michali.